NVX 208Alternative Names: NVX-208
Latest Information Update: 15 Mar 2017
At a glance
- Originator NuvOx Pharma
- Developer NuvOx Pharma; University of Arkansas for Medical Sciences
- Class Diagnostic agents; Fluorinated hydrocarbons; Fluorocarbons; Radiation-sensitising agents; Radiosensitisers; Small molecules
- Mechanism of Action Oxygen carriers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Stroke